MICHELLE ZEBROWSKI: Open Payments
NPI 1679847651 · GRIFFIN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,793 in 80 payments from 13 companies in 2025. Trend: 2023 $1,259 · 2024 $2,188 · 2025 $1,793
Food & beverage: $1,781Education: $12
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 19 | $488 |
| ABBVIE INC. | 20 | $376 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $211 |
| Ardelyx, Inc. | 9 | $188 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $136 |
| Madrigal Pharmaceuticals | 3 | $84 |
| Janssen Scientific Affairs, LLC | 1 | $67 |
| Aimmune Therapeutics, Inc. | 3 | $65 |
| Phathom Pharmaceuticals, Inc. | 3 | $59 |
| Gilead Sciences, Inc. | 2 | $37 |
Products named: TREMFYA, ENTYVIO, IBSRELA, RINVOQ, XIFAXAN, SKYRIZI, LINZESS, REZDIFFRA.
Industry payments across GA — which companies pay providers there.
